Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Gilbert, Amy E ^a,b   Karagiannis, Panagiotis ^a   Dodev, Tihomir ^c   Koers, Alexander ^d   Lacy, Katie ^a   Josephs, Debra H ^a   Takhar, Pooja ^c   Geh, Jenny L C ^b   Healy, Ciaran ^b   Harries, Mark ^a   Acland, Katharine M ^b   Rudman, Sarah M ^b   Beavil, Rebecca L ^c   Blower, Philip J ^d   Beavil, Andrew J ^c   Gould, Hannah J ^c   Spicer, James ^b   Nestle, Frank O ^a   Karagiannis, Sophia N ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; CANCER ANTIBODY; IMMUNOGLOBULIN G;

ADULT; AGED; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ARTICLE; CANCER PATIENT; CANCER STAGING; CELLULAR IMMUNITY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IN VITRO STUDY; MALE; MELANOMA; MELANOMA CELL; MEMORY CELL; SKIN FIBROBLAST; B LYMPHOCYTE; BLOOD; CASE CONTROL STUDY; CELL LINE; CHEMISTRY; DISEASE COURSE; FIBROBLAST; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; METHODOLOGY; TIME; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; B-LYMPHOCYTES; CASE-CONTROL STUDIES; CELL LINE; CELL LINE, TUMOR; COHORT STUDIES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLASTS; HUMANS; IMMUNE SYSTEM; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; MELANOMA; TIME FACTORS;

EID: 79955778025     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019330     Document Type: Article

References (60)

1. Lens MB, Dawes M, (2004) Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. British Journal of Dermatology 150: 179-185.
2. Cummins DL, Cummins JM, Pantle H, Silverman MA, Leonard AL, et al. (2006) Cutaneous Malignant Melanoma. Mayo Clinic Proceedings 81: 500-507.
3. Nestle FO, Halpern AC, (2007) Melanoma. In: JL B, JL J, RP R, editors. Dermatology. 2 ed St. Louis Mosby Elsevier.
4. Kalialis LV, Drzewiecki KT, Klyver H, (2009) Spontaneous regression of metastases from melanoma: review of the literature. [Review]. Melanoma Research October 19: 275-282.
5. Schadendorf D, Algarra SM, Bastholt L, Cinat G, Dreno B, et al. (2009) Immunotherapy of distant metastatic disease. Annals of Oncology 20: vi41-vi50.
6. Vajdic CM, van Leeuwen MT, Webster AC, McCredie MRE, Stewart JH, et al. (2009) Cutaneous Melanoma Is Related to Immune Suppression in Kidney Transplant Recipients. Cancer Epidemiology Biomarkers & Prevention 18: 2297-2303.
7. Kirkwood JM, Tarhini AA, Panelli MC, Moschos SJ, Zarour HM, et al. (2008) Next Generation of Immunotherapy for Melanoma. J Clin Oncol 26: 3445-3455.
8. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, et al. (1999) Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5: 677-685.
9. Vence L, Palucka AK, Fay JW, Ito T, Liu Y-J, et al. (2007) Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proceedings of the National Academy of Sciences 104: 20884-20889.
10. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME, (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8: 299-308.
11. Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, et al. (2006) Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Annals of Oncology 17: 563-570.
12. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, et al. (2010) Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients. Clinical Cancer Research 16: 2646-2655.
13. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med 363 (8): 711-723.
14. Andreu P, Johansson M, Affara NI, Pucci F, Tan T, et al. (2010) FcR[gamma] Activation Regulates Inflammation-Associated Squamous Carcinogenesis. Cancer Cell 17: 121-134.
15. Qin Z, Richter G, Schuler T, Ibe S, Cao X, et al. (1998) B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 4: 627-630.
16. DiLillo DJ, Yanaba K, Tedder TF, (2010) B Cells Are Required for Optimal CD4+ and CD8+ T Cell Tumor Immunity: Therapeutic B Cell Depletion Enhances B16 Melanoma Growth in Mice. J Immunol 184: 4006-4016.
17. Takahashi T, Johnson TD, Nishinaka Y, Morton DL, Irie RF, (1999) IgM Anti-Ganglioside Antibodies Induced by Melanoma Cell Vaccine Correlate with Survival of Melanoma Patients. 112: 205-209.
18. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, et al. (1996) Loss of Functional Beta2-Microglobulin in Metastatic Melanomas From Five Patients Receiving Immunotherapy. J Natl Cancer Inst 88: 100-108.
19. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD, (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991-998.
20. Houghton AN, Gold JS, Blachere NE, (2001) Immunity against cancer: lessons learned from melanoma. Current Opinion in Immunology 13: 134-140.
21. Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S, (2003) Tumors as elusive targets of T-cell-based active immunotherapy. Trends in Immunology 24: 334-341.
22. Kirkwood JM, Lorigan P, Hersey P, Hauschild A, Robert C, et al. Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma. Clinical Cancer Research 16: 1042-1048.
23. Mittelman A, Chen ZJ, Yang H, Wong GY, Ferrone S, (1992) Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proceedings of the National Academy of Sciences of the United States of America 89: 466-470.
24. Perez DG, Suman VJ, Fitch TR, III TA, Morton RF, et al. (2009) Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma. Cancer 115: 119-127.
25. Lewis MG, Ikonopisov RL, Nairn RC, Phillips TM, Fairley GH, et al. (1969) Tumour-specific Antibodies in Human Malignant Melanoma and their Relationship to the Extent of the Disease. Br Med J 3: 547-552.
26. Stockert E, Jager E, Chen Y-T, Scanlan MJ, Gout I, et al. (1998) A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens. J Exp Med 187: 1349-1354.
27. Huang SKS, Okamoto T, Morton DL, Hoon DSB, (1998) Antibody Responses to Melanoma//Melanocyte Autoantigens in Melanoma Patients. 111: 662-667.
28. Chen Y-T, Scanlan MJ, Sahin U, Türeci Ö, Gure AO, et al. (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proceedings of the National Academy of Sciences 94: 1914-1918.
29. Sahin U, Türeci O, Schmitt H, Cochlovius B, Johannes T, et al. (1995) Human neoplasms elicit multiple specific immune responses in the autologous host. Proceedings of the National Academy of Sciences of the United States of America 92: 11810-11813.
30. Chen Y-T, Gure AO, Tsang S, Stockert E, Jäger E, et al. (1998) Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proceedings of the National Academy of Sciences of the United States of America 95: 6919-6923.
31. Yamaguchi H, Furukawa K, Fortunato SR, Livingston PO, Lloyd KO, et al. (1987) Cell-surface antigens of melanoma recognized by human monoclonal antibodies. Proceedings of the National Academy of Sciences of the United States of America 84: 2416-2420.
32. Kirkwood JM, Robinson JE, (1990) Human IgG and IgM monoclonal antibodies against autologous melanoma produced by Epstein-Barr-virus-transformed B lymphocytes. Cancer Immunology, Immunotherapy 32: 228-234.
33. Yeilding NM, Gerstner C, Kirkwood JM, (1992) Analysis of two human monoclonal antibodies against melanoma. International Journal of Cancer 52: 967-973.
34. Punt CJA, Barbuto JAM, Zhang H, Grimes WJ, Hatch KD, et al. (1994) Anti-tumor antibody produced by human tumor-infiltrating and peripheral blood B lymphocytes. Cancer Immunology, Immunotherapy 38: 225-232.
35. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, et al. (2004) An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 10: 871-875.
36. Lanzavecchia A, Corti D, Sallusto F, (2007) Human monoclonal antibodies by immortalization of memory B cells. Current Opinion in Biotechnology 18: 523-528.
37. Gril B, Palmieri D, Bronder JL, Herring JM, Vega-Valle E, et al. (2008) Effect of Lapatinib on the Outgrowth of Metastatic Breast Cancer Cells to the Brain. J Natl Cancer Inst 100: 1092-1103.
38. Stove C, Stove V, Derycke L, Van Marck V, Mareel M, et al. (2003) The Heregulin//Human Epidermal Growth Factor Receptor as a New Growth Factor System in Melanoma with Multiple Ways of Deregulation. 121: 802-812.
39. Zhang H, Lake DF, Barbuto JAM, Bernstein RM, Grimes WJ, et al. (1995) A Human Monoclonal Antimelanoma Single-Chain Fv Antibody Derived from Tumor-infiltrating Lymphocytes. Cancer Res 55: 3584-3591.
40. Karagiannis P, Singer J, Hunt J, Gan S, Rudman S, et al. (2009) Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/ neu-positive tumour cells. Cancer Immunology, Immunotherapy 58: 915-930.
41. Cai X, Garen A, (1995) Anti-melanoma antibodies from melanoma patients immunized with genetically modified autologous tumor cells: selection of specific antibodies from single-chain Fv fusion phage libraries. Proceedings of the National Academy of Sciences of the United States of America 92: 6537-6541.
42. Wewetzer K, Heiniger C, Seilheimer B, (1996) An improved cell-ELISA for the differential screening of antibodies against cell surface molecules of viable adherent Schwann cells. Journal of Immunological Methods 191: 171-178.
43. Hodi FS, (2006) Well-Defined Melanoma Antigens as Progression Markers for Melanoma: Insights into Differential Expression and Host Response Based on Stage. Clinical Cancer Research 12: 673-678.
44. Campoli MR, Chang C-C, Kageshita T, Wang X, McCarthy JB, et al. (2004) Human High Molecular Weight-Melanoma-Associated Antigen (HMW-MAA): A Melanoma Cell Surface Chondroitin Sulfate Proteoglycan (MSCP) with Biological and Clinical Significance. Critical Reviews Immunology 24: 30.
45. Wistuba II, Bryant David, Behrens C, Milchgrub S, Virmani AK, et al. (1999) Comparison of Features of Human Lung Cancer Cell Lines and Their Corresponding Tumors. Clinical Cancer Research 5: 991-1000.
46. Carpenter EL, Mick R, Rech AJ, Beatty GL, Colligon TA, et al. (2009) Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers. Clin Cancer Res 15: 4277-4287.
47. Shimbo T, Tanemura A, Yamazaki T, Tamai K, Katayama I, et al. (2010) Serum Anti-BPAG1 Auto-Antibody Is a Novel Marker for Human Melanoma. PLoS One 5: e10566.
48. Swann JB, Smyth MJ, (2007) Immune surveillance of tumors. The Journal of Clinical Investigation 117: 1137-1146.
49. Bouaziz J-D, Calbo S, Maho-Vaillant M, Saussine A, Bagot M, et al. IL-10 produced by activated human B cells regulates CD4+ T-cell activation in vitro. European Journal of Immunology 40: 2686-2691.
50. Weiner LM, Surana R, Wang S, (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 10: 317-327.
51. Clynes R, Towers T, Presta L, Ravetch J, (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nature Med 6: 443-446.
52. Karagiannis SN, Bracher MG, Hunt J, McCloskey N, Beavil RL, et al. (2007) IgE-Antibody-Dependent Immunotherapy of Solid Tumors: Cytotoxic and Phagocytic Mechanisms of Eradication of Ovarian Cancer Cells. J Immunol 179: 2832-2843.
53. Karagiannis Sophia N, Wang Q, East N, Burke F, Riffard S, et al. (2003) Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. European Journal of Immunology 33: 1030-1040.
54. Hudis CA, (2007) Trastuzumab-- Mechanism of Action and Use in Clinical Practice. N Engl J Med 357: 39-51.
55. Glennie MJ, French RR, Cragg MS, Taylor RP, (2007) Mechanisms of killing by anti-CD20 monoclonal antibodies. Molecular Immunology 44: 3823-3837.
56. Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, et al. (2008) CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proceedings of the National Academy of Sciences 105: 20410-20415.
57. Pinna Debora, Corti Davide, Jarrossay David, Sallusto Federica, Lanzavecchia A, (2009) Clonal dissection of the human memory B-cell repertoire following infection and vaccination. European Journal of Immunology 39: 1260-1270.
58. Kwakkenbos MJ, Diehl SA, Yasuda E, Bakker AQ, van Geelen CMM, et al. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat Med 16: 123-128.
59. Slamon D, Clark G, Wong S, Levin W, Ullrich A, et al. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182.
60. Balch CM, Gershenwald JE, Soong S-J, Thompson JF, Atkins MB, et al. (2009) Final Version of 2009 AJCC Melanoma Staging and Classification. J Clin Oncol 27: 6199-6206.